Literature DB >> 18647347

Hodgkin Reed-Sternberg cells express 15-lipoxygenase-1 and are putative producers of eoxins in vivo: novel insight into the inflammatory features of classical Hodgkin lymphoma.

Hans-Erik Claesson1, William J Griffiths, Asa Brunnström, Frida Schain, Erik Andersson, Stina Feltenmark, Hélène A Johnson, Anna Porwit, Jan Sjöberg, Magnus Björkholm.   

Abstract

Classical Hodgkin lymphoma has unique clinical and pathological features and tumour tissue is characterized by a minority of malignant Hodgkin Reed-Sternberg cells surrounded by inflammatory cells. In the present study, we report that the Hodgkin lymphoma-derived cell line L1236 has high expression of 15-lipoxygenase-1 and that these cells readily convert arachidonic acid to eoxin C(4), eoxin D(4) and eoxin E(4). These mediators were only recently discovered in human eosinophils and mast cells and found to be potent proinflammatory mediators. Western blot and immunocytochemistry analyses of L1236 cells demonstrated that 15-lipoxygenase-1 was present mainly in the cytosol and that the enzyme translocated to the membrane upon calcium challenge. By immunohistochemistry of Hodgkin lymphoma tumour tissue, 15-lipoxygenase-1 was found to be expressed in primary Hodgkin Reed-Sternberg cells in 17 of 20 (85%) investigated biopsies. The enzyme 15-lipoxygenase-1, however, was not expressed in any of 10 biopsies representing nine different subtypes of non-Hodgkin lymphoma. In essence, the expression of 15-lipoxygenase-1 and the putative formation of eoxins by Hodgkin Reed-Sternberg cells in vivo are likely to contribute to the inflammatory features of Hodgkin lymphoma. These findings may have important diagnostic and therapeutic implications in Hodgkin lymphoma. Furthermore, the discovery of the high 15-lipoxygenase-1 activity in L1236 cells demonstrates that this cell line comprises a useful model system to study the chemical and biological roles of 15-lipoxygenase-1.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18647347     DOI: 10.1111/j.1742-4658.2008.06570.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  6 in total

1.  Biosynthesis of 14,15-hepoxilins in human l1236 Hodgkin lymphoma cells and eosinophils.

Authors:  Asa Brunnström; Mats Hamberg; William J Griffiths; Bengt Mannervik; Hans-Erik Claesson
Journal:  Lipids       Date:  2010-10-29       Impact factor: 1.880

2.  The Kaposi's sarcoma-associated herpesvirus (KSHV)-induced 5-lipoxygenase-leukotriene B4 cascade plays key roles in KSHV latency, monocyte recruitment, and lipogenesis.

Authors:  Neelam Sharma-Walia; Karthic Chandran; Kinjan Patel; Mohanan Valiya Veettil; Alexandru Marginean
Journal:  J Virol       Date:  2013-12-11       Impact factor: 5.103

3.  Metabolism of anandamide into eoxamides by 15-lipoxygenase-1 and glutathione transferases.

Authors:  Pontus K A Forsell; Asa Brunnström; Malin Johannesson; Hans-Erik Claesson
Journal:  Lipids       Date:  2012-06-09       Impact factor: 1.880

4.  Predictive significance of arachidonate 15-lipoxygenase for eosinophilic chronic rhinosinusitis with nasal polyps.

Authors:  Zhuoping Liang; Bing Yan; Chang Liu; Ruyu Tan; Chengshuo Wang; Luo Zhang
Journal:  Allergy Asthma Clin Immunol       Date:  2020-09-16       Impact factor: 3.406

5.  Asthmatics exhibit altered oxylipin profiles compared to healthy individuals after subway air exposure.

Authors:  Susanna L Lundström; Bettina Levänen; Malin Nording; Anna Klepczynska-Nyström; Magnus Sköld; Jesper Z Haeggström; Johan Grunewald; Magnus Svartengren; Bruce D Hammock; Britt-Marie Larsson; Anders Eklund; Åsa M Wheelock; Craig E Wheelock
Journal:  PLoS One       Date:  2011-08-29       Impact factor: 3.240

6.  Interleukin-4-mediated 15-lipoxygenase-1 trans-activation requires UTX recruitment and H3K27me3 demethylation at the promoter in A549 cells.

Authors:  Hongya Han; Dawei Xu; Cheng Liu; Hans-Erik Claesson; Magnus Björkholm; Jan Sjöberg
Journal:  PLoS One       Date:  2014-01-20       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.